Skip to main content
A

Ab&B Bio-Tech CO., LTD. JS — Investor Relations & Filings

Ticker · 2627 HKEX Manufacturing
Filings indexed 58 across all filing types
Latest filing 2026-05-08 Regulatory Filings
Country HK Hong Kong
Listing HKEX 2627

About Ab&B Bio-Tech CO., LTD. JS

http://www.abbbio.com

Ab&B Bio-Tech CO., LTD. JS is a biopharmaceutical company engaged in the research, development, manufacturing, and commercialization of human vaccines and biological preparations that confer active immunity. The company's mission centers on developing globally innovative vaccines and utilizing new technologies to improve traditional vaccines. Its comprehensive pipeline targets infectious diseases and includes candidates across viral, bacterial, conjugate, subunit, and mRNA platforms. The primary commercial product is the Quadrivalent Subunit Influenza Vaccine, approved for individuals aged six months and above. Advanced pipeline assets, such as the 23-valent Pneumococcal Polysaccharide Vaccine and the Freeze-dried Human Rabies Vaccine (Human Diploid Cell), have completed Phase I clinical trials. R&D operations are supported by facilities in Shanghai and Taizhou, with the company emphasizing scientific validation through publications in international journals.

Recent filings

Filing Released Lang Actions
FORM OF PROXY FOR THE FIRST EXTRAORDINARY GENERAL MEETING OF 2026 TO BE HELD ON WEDNESDAY, MAY 27, 2026 AND ANY ADJOURNMENT THEREOF
Regulatory Filings
2026-05-08 English
(1) ABOLITION OF THE SUPERVISORY COMMITTEE (2) AMENDMENTS TO THE ARTICLES OF ASSOCIATION (3) AMENDMENTS TO CERTAIN INTERNAL CORPORATE GOVERNANCE POLICIES (4) APPOINTMENT OF INDEPENDENT NON-EXECUTIVE D
Regulatory Filings
2026-05-08 English
NOTICE OF THE FIRST EXTRAORDINARY GENERAL MEETING OF 2026
Regulatory Filings
2026-05-07 English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 30 APRIL 2026
Regulatory Filings
2026-05-04 English
RESUMPTION GUIDANCE AND CONTINUED SUSPENSION OF TRADING
Regulatory Filings
2026-04-29 English
(I) NOMINATION OF INDEPENDENT NON-EXECUTIVE DIRECTOR (II) CHANGE OF BOARD COMMITTEE MEMBERS AND (III) PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION
Board/Management Information Classification · 1% confidence The document is a corporate announcement by a Hong Kong–listed company regarding (i) the nomination of an independent non-executive director, (ii) changes to board committee membership, and (iii) proposed amendments to the Articles of Association. These are changes to the board and its governance structure, fitting the definition of a Board/Management Information announcement. Therefore, it should be classified as MANG.
2026-04-24 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.